TSPYL2 and diabetic kidney disease: Taken together, our results demonstrate that targeting CDA1 in established DKD is able to reduce TGFβ signaling, leading to reduced gene expression and protein accumulation of molecules associated with fibrosis in the kidney, and can potentially retard DKD progression.